Deuruxolitinib (CTP-543)

Medical professionals may also email us at AAclinicaltrial_inquiries@concertpharma.com for more information about deuruxolitinib study participation.

THRIVE-AA1: A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT04518995

THRIVE-AA2: A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT04797650 

Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata

Status: Active, Not Recruiting
https://clinicaltrials.gov/ct2/show/NCT04784533

Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Evaluating the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03137381

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03941548

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Evaluating the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Status: Completed
https://clinicaltrials.gov/ct2/show/NCT03811912

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Evaluating long-term safety of CTP-543 and to assessing long-term effects of CTP-543 in adult patients with chronic, moderate-to-severe alopecia areata who completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial.

Status: Enrolling by Invitation
https://clinicaltrials.gov/ct2/show/NCT03898479

Concert is committed to developing innovative medicines for autoimmune disorders.

Participation in our clinical trials plays a vital role in helping develop new medicines. While we do not currently offer investigational therapies outside of our clinical trials, you and your physician may determine that enrolling in a trial may be an option for you. For more information about Concert’s ongoing clinical trial programs, please reference the trials listed above.